Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

Neal Young, MD
Published: Saturday, Dec 05, 2015



Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

In this phase II study, 92 patients were accrued. Results showed an increase in immunologic response rate, robust blood cell counts, and an improvement in survival. There was one patient death on the study, Young adds.

These results suggest that the immediate addition of eltrombopag with standard immunosuppression may salvage and expand residual hematopoietic stem cells in aplastic anemia.

<<< View more from the 2015 ASH Annual Meeting



Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

In this phase II study, 92 patients were accrued. Results showed an increase in immunologic response rate, robust blood cell counts, and an improvement in survival. There was one patient death on the study, Young adds.

These results suggest that the immediate addition of eltrombopag with standard immunosuppression may salvage and expand residual hematopoietic stem cells in aplastic anemia.

<<< View more from the 2015 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x